Patient Activation To Increase Colon Cancer Screening (THE CHAT STUDY)
I. To test a patient activation intervention to improve colorectal cancer (CRC) screening
rates using fecal occult blood test (FOBT) among male and female patients 50 years and older
from the East Central Columbus Neighborhood Health Center.
I. To assess if there is a change in knowledge and attitudes about CRC screening after
watching the educational video.
II. To assess the effectiveness of providing communication skills training for improving
discussion focusing on CRC screening during the patient-provider visit.
OUTLINE: Patients are randomized to 1 of 2 arms prior to a medical visit.
ARM I (Education only): Patients receive CRC and CRC screening information by an educational
video and a brochure with healthy hints to prevent CRC.
ARM II (Education and patient activation): Patients receive CRC and CRC screening
information and communication skills training (patient activation) intervention by
educational video and brochure and a brochure about healthy hints to prevent CRC.
After the medical visit, patients' medical records are reviewed at 1 month and 2 months
after the visit to document CRC screening completion.
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening
Completion rate of CRC screening
A test of two proportions will be used. If the two groups are different at baseline with respect to key covariates, then a logistic regression model will be used to assess the effect of the intervention on CRC screening controlling for possible confounding variables. The variables that differ between the two groups will be tested as confounders using risk-factor modeling. Summary statistics will be used to describe the time point that subjects receive CRC screening, either after the medical visit or after telephone barriers counseling, and relevant comparisons made.
Up to 2 months
Ohio State University Comprehensive Cancer Center
United States: Institutional Review Board
|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center||Columbus, Ohio 43210-1240|